Tag: Graft versus Host Disease

May 21, 2019

Kalytera Announces Engagement of Echelon Wealth Partners to Assist with Review of Potential Out-License Opportunities for Commercial Rights to GVHD Products

Kalytera Therapeutics, Inc. (TSXV:KALY, OTCQB:KALTF)(the "Company" or "Kalytera") has engaged Echelon Wealth Partners to determine the value, on a risk-adjusted...
April 17, 2019

Kalytera Therapeutics Announces Filing of Short Form Prospectus

Kalytera Therapeutics, Inc. (the “Company”, or “Kalytera”) (TSXV:KALY) (OTCQB:KALTF) announced today that it has filed a final short form prospectus...
April 3, 2019

Kalytera Therapeutics Announces Short Form Prospectus Offering of Units

Kalytera Therapeutics, Inc. (TSXV:KALY, OTCQB:KALTF) announced that it has filed a preliminary short form prospectus with the securities regulatory authorities...
March 22, 2019

Kalytera Reports Data for First Cohort in Phase 2 Clinical Study Evaluating CBD in Prevention of Acute GVHD

Kalytera Therapeutics, Inc. (TSXV:KALY, OTC:KALTF) (the "Company" or "Kalytera") today announced positive data from its ongoing Phase 2 clinical study evaluating...
March 6, 2019

Kalytera Announces Initiation of Study KAL-07 – Food Effect Study

Kalytera Therapeutics, Inc. (TSXV:KALY, OTC:KALTF) (the "Company" or "Kalytera") today announced that it has initiated a food effect study (“Study...
February 26, 2019

Kalytera Announces Share Issuance for January Invoices under Payments Agreements with Salzman Group

Kalytera Therapeutics, Inc. (TSXV:KALY, OTCQB:KALTF) (the "Company" or "Kalytera") today announced that the Company has elected to issue 15,262,540 common...
February 5, 2019

Kalytera Reports Additional Positive Data for CBD in Prevention of Acute GVHD

Kalytera Therapeutics, Inc. (TSXV:KALY, OTCQB:KALTF) (the "Company" or "Kalytera") today announced additional positive interim data from its ongoing Phase 2...